Globe NewsWire News Distribution Service

Details

Written by Globe NewsWire Press Releases

Category: Globe NewsWire News Distribution Service

Published: 08 February 2025

Created: 08 February 2025

Last Updated: 08 February 2025

TARRYTOWN, N.Y., Feb. 08, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first presentation of positive results from the Phase 3 QUASAR trial investigating EYLEA HD® (aflibercept) Injection 8 mg for the treatment of patients with macular edema following retinal vein occlusion (RVO), including those with central, branch and hemiretinal vein occlusions.…

Posted: 2025-02-08 22:40:00

Get Full News Story On GlobeNewsWire Press Release Service

Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.

• Prev
• Next

Related Bing News Search Results

Press Release: EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting - Newscast

Regeneron falls after appeals court ruling in Eylea case (update)

Fri, 14 Mar 2025 11:35:32 GMT Adds Regeneron comment Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 1.6% after the company's loss against Amgen (NASDAQ:AMGN) in a patent case over Regeneron's blockbuster Eylea drug was affirmed ...

Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®

Mon, 24 Feb 2025 16:00:00 GMT Aflibercept is an inhibitor of the vascular endothelial growth factor (VEGF), which plays a key role in the abnormal formation of blood vessels in the retina, leading to vision impairment. 1) Eylea ® ...

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Mon, 17 Feb 2025 22:00:00 GMT In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg.

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Mon, 17 Feb 2025 22:00:00 GMT In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept ... the Alvotech website shall be deemed part of this press release. Please visit our investor portal, and our ...